BackEvaxion Biotech A/S Overview

Evaxion Biotech A/S Inventory

Latest inventory for EVAX: $0.

Get informed when a big investor buys or sells

+ Follow
Inventory
$0.00

Peer trimmed avg / median

Loading

Evaxion Biotech A/S Inventory History

Loading

Evaxion Biotech A/S vs. peers: Inventory Comparison

Loading

Evaxion Biotech A/S Inventory Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Evaxion Biotech A/S (EVAX) FAQ

Evaxion Biotech A/S (EVAX) currently reports a inventory of $0 as of June 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Evaxion Biotech A/S's inventory history and peer comparisons.

Evaxion Biotech A/S's inventory changed from $0 to $0 (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Evaxion Biotech A/S reported $0 in inventory as of June 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current inventory of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Evaxion Biotech A/S, and consider following EVAX for alerts when major investors trade the stock.

Evaxion Biotech A/S is classified in the Healthcare sector. On inventory, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EVAX with unrelated industries.